PBA
MCID: PSD088
MIFTS: 37

Pseudobulbar Affect (PBA)

Categories: Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Pseudobulbar Affect

MalaCards integrated aliases for Pseudobulbar Affect:

Name: Pseudobulbar Affect 53
Emotional Lability 53 29 6
Involuntary Emotional Expression Disorder 53 72
Pathological Crying and Laughing 53
Emotional Incontinence 53
Mood Swings 72
Pba 53

Classifications:



External Ids:

UMLS 72 C0085633 C3161187

Summaries for Pseudobulbar Affect

NIH Rare Diseases : 53 Pseudobulbar affect (PBA) is a condition characterized by episodes of sudden, uncontrollable and inappropriate episodes of crying or laughing. The condition can be embarrassing and disruptive to daily life. It typically occurs in people with certain neurological conditions or injuries that affect the way the brain controls emotion. It is common in stroke survivors and people with conditions such as dementia, multiple sclerosis, Lou Gehrig's disease (ALS) and traumatic brain injury. PBA is thought to affect more than one million people in the United States. The goal of treatment is to reduce the severity and frequency of emotional outbursts. Treatment may include the use of antidepressants and/or a combination of dextromethorphan and quinidine.

MalaCards based summary : Pseudobulbar Affect, also known as emotional lability, is related to progressive bulbar palsy and kuru, and has symptoms including mental and behavioral signs and symptoms, nervousness and demoralization and apathy. An important gene associated with Pseudobulbar Affect is CYP2D6 (Cytochrome P450 Family 2 Subfamily D Member 6). The drugs Citalopram and Rivastigmine have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and amygdala.

Wikipedia : 75 Pseudobulbar affect (PBA), or emotional incontinence, is a type of emotional disturbance characterized... more...

Related Diseases for Pseudobulbar Affect

Diseases related to Pseudobulbar Affect via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 89)
# Related Disease Score Top Affiliating Genes
1 progressive bulbar palsy 11.6
2 kuru 11.3
3 colloid cysts of third ventricle 11.3
4 childhood-onset cerebral x-linked adrenoleukodystrophy 11.3
5 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids 11.1
6 amyotrophic lateral sclerosis 1 10.6
7 lateral sclerosis 10.6
8 traumatic brain injury 10.5
9 attention deficit-hyperactivity disorder 10.5
10 huntington disease 10.3
11 brain injury 10.3
12 multiple sclerosis 10.3
13 malaria 10.3
14 oppositional defiant disorder 10.2
15 mood disorder 10.2
16 parkinson disease, late-onset 10.2
17 depression 10.2
18 triiodothyronine receptor auxiliary protein 10.1
19 hepatitis c virus 10.1
20 x-linked alport syndrome 10.1
21 thalassemia 10.1
22 alport syndrome 10.1
23 end stage renal failure 10.1
24 hypoglycemia 10.1
25 sickle cell disease 10.1
26 back pain 10.1
27 chronic pain 10.1
28 alzheimer disease 10.1
29 stroke, ischemic 10.1
30 acute cystitis 10.1
31 mental depression 10.1
32 cerebrovascular disease 10.1
33 substance abuse 10.0
34 endogenous depression 10.0
35 cardiac arrhythmia 9.9
36 meningioma, radiation-induced 9.9
37 meningioma, familial 9.9
38 anxiety 9.9
39 major depressive disorder 9.9
40 primary lateral sclerosis, adult, 1 9.9
41 major affective disorder 8 9.9
42 major affective disorder 9 9.9
43 respiratory failure 9.9
44 spinal meningioma 9.9
45 dementia 9.9
46 cerebral palsy 9.9
47 constipation 9.9
48 bipolar disorder 9.9
49 skull base meningioma 9.9
50 secretory meningioma 9.9

Graphical network of the top 20 diseases related to Pseudobulbar Affect:



Diseases related to Pseudobulbar Affect

Symptoms & Phenotypes for Pseudobulbar Affect

UMLS symptoms related to Pseudobulbar Affect:


mental and behavioral signs and symptoms, nervousness, demoralization and apathy, other signs and symptoms involving emotional state, signs and symptoms involving emotional state, pregnancy mood swing

Drugs & Therapeutics for Pseudobulbar Affect

Drugs for Pseudobulbar Affect (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 236)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Citalopram Approved Phase 4 59729-33-8 2771
2
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
3
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
4
Desogestrel Approved Phase 4 54024-22-5 40973
5
Drospirenone Approved Phase 4 67392-87-4 68873
6
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
7
Lithium carbonate Approved Phase 4 554-13-2
8
Norepinephrine Approved Phase 4 51-41-2 439260
9
Topiramate Approved Phase 4 97240-79-4 5284627
10
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
11
Promethazine Approved, Investigational Phase 4 60-87-7 4927
12
Suvorexant Approved, Investigational Phase 4 1030377-33-3
13
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
14
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
15
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
16
Quinidine Approved, Investigational Phase 4 56-54-2 441074
17
Allopurinol Approved Phase 4 315-30-0 2094
18
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 4 303-98-0 5281915
19
Genistein Investigational Phase 4 446-72-0 5280961
20
Daidzein Experimental Phase 4 486-66-8 5281708
21 Parasympatholytics Phase 4
22 Antiparkinson Agents Phase 4
23 Psychotropic Drugs Phase 4
24 Tranquilizing Agents Phase 4
25 Anticonvulsants Phase 4
26 Cholinesterase Inhibitors Phase 4
27 Antidepressive Agents Phase 4
28 Serotonin Uptake Inhibitors Phase 4
29 Antidepressive Agents, Second-Generation Phase 4
30 Neurotransmitter Uptake Inhibitors Phase 4
31 Serotonin Agents Phase 4
32 Estrogens Phase 4
33 Quetiapine Fumarate Phase 4 111974-72-2
34 Antipsychotic Agents Phase 4
35 Natriuretic Agents Phase 4
36 diuretics Phase 4
37 Mineralocorticoids Phase 4
38 Mineralocorticoid Receptor Antagonists Phase 4
39 Dacuronium Phase 4
40 Drospirenone and ethinyl estradiol combination Phase 4
41 N-monoacetylcystine Phase 4
42 Antidotes Phase 4
43 Expectorants Phase 4
44 Antiviral Agents Phase 4
45 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
46 Venlafaxine Hydrochloride Phase 4
47 Red Clover Phase 4
48 Soy Bean Phase 4
49 Phytoestrogens Phase 4
50 Hypoglycemic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 108)
# Name Status NCT ID Phase Drugs
1 Clinical Protocol of a Prospective, Open-label Study to Assess the Safety and Efficacy of Nuedexta (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Alzheimer's Disease Unknown status NCT01832350 Phase 4 Nuedexta (20/10)
2 A Multicenter, Double Blind Trial to Compare the Efficacy and Safety of Escitalopram With Placebo in Patients With Acute Stroke for the Prevention of Poststroke Depression and Related Symptoms (Emotional Incontinence, Anger Proneness), and for Improvement of Neurologic, Cognitive Function and Quality of Life Unknown status NCT01278498 Phase 4 Escitalopram;sugar pill
3 A Study to Assess the Safety, Tolerability and Effectiveness of Nuedexta (Dextromethorphan 20 mg/Quinidine 10 mg) in the Treatment of Pseudobulbar Affect (PBA) Completed NCT01799941 Phase 4 Nuedexta (DM 20 mg/Q 10 mg)
4 Double Blind Placebo Controlled Study of Depakote (Divalproex Sodium) in Children With Temper Outbursts and Severe Mood Swings Completed NCT02078596 Phase 4 Divalproex
5 Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease Completed NCT00104442 Phase 4 Rivastigmine
6 A Comparative Efficacy of Low-dose Combine Oral Contraceptives Containing Desogestrel 150 mg and Drospirenone 3 mg on Premenstrual Symptoms Completed NCT01482338 Phase 4 EE 20 microgram with desogestrel 150 mg;EE 20 microgram with drospirenone 3 mg
7 Open-Label Study of N-Acetylcysteine in Children and Adolescents Ages 5-17 With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder Completed NCT02357290 Phase 4 Open-label Treatment with N-Acetylcysteine
8 Treatment of Bipolar Type II Major Depression Completed NCT00602537 Phase 4 Venlafaxine;Lithium Carbonate
9 Impact of Phytoestrogens on Serum Lipids in Postmenopausal Women Completed NCT01497977 Phase 4 phytoestrogens;phytoestrogens
10 Quetiapine Plus Topiramate or Placebo for Bipolar Mania & Cannabis Use in Adolescents Completed NCT00393978 Phase 4 Quetiapine and placebo;Quetiapine and Topiramate
11 Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder Completed NCT00533117 Phase 4 Fluoxetine
12 A Prospective, Randomized, Multicenter, Open-Label, Pilot Study to Investigate Medication Adherence & Patient Reported Symptom Occurrence & Interference w/ Daily Life Comparing Envarsus XR® & Immediate Release Tacrolimus in Adult Renal Transplant Recipients (SIMPLE) Not yet recruiting NCT03979365 Phase 4 Envarsus XR;Tacrolimus twice daily
13 A Double-Blind Sequential Parallel Study of Suvorexant (Belsomra) for the Treatment of Bipolar Depression With Insomnia Not yet recruiting NCT03764683 Phase 4 Suvorexant (Belsomra);Placebo
14 A Study to Assess Effectiveness, Safety, and Health-related Outcomes of NUEDEXTA® (Dextromethorphan Hydrobromide and Quinidine Sulfate) for the Treatment of Pseudobulbar Affect (PBA) in Nursing Home Patients Terminated NCT02496039 Phase 4 NUEDEXTA®
15 An Open Label, Naturalistic Study With Allopurinol Augmentation for Prevention of Mania in Bipolar Disorder Terminated NCT00732251 Phase 4 Allopurinol
16 A Phase 3 Study of the Use of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder Unknown status NCT01217775 Phase 3 PH80;Placebo intranasal spray
17 Dienogest Versus Luteal Phase Fluoxetine in the Management of Premenstrual Syndrome: A Randomized Double Blind Placebo Controlled Trial Unknown status NCT02427334 Phase 3 Dienogest;Fluoxetine;Placebo
18 The Synergistic Use of Combined Oral Contraceptives and Fluoxetine Versus Combined Oral Contraceptives in the Management of Severe Premenstrual Syndrome: A Randomized Double Blind Placebo Controlled Trial Unknown status NCT02488538 Phase 3 Combined oral contraceptives;Fluoxetine;Combined oral contraceptives placebo;Fluoxetine placebo
19 Does Adding Combined Oral Contraceptives to Fluoxetine Improve the Management of Premenstrual Syndrome? A Double Blind Placebo Controlled Study. Unknown status NCT02562053 Phase 3 Fluoxetine;Combined oral contraceptives;Placebo 1;Placebo 2
20 An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect. Completed NCT00056524 Phase 3 AVP-923
21 Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients Completed NCT00050232 Phase 3 AVP-923
22 A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS) Completed NCT00573443 Phase 3 dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg;dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg;Placebo
23 An Open Label Phase 3 Study of Fortigel Testosterone Gel 2% in Hypogonadal Males Completed NCT00522431 Phase 3 Testosterone
24 A Double-Blind, 9-Week Extension Study Evaluating the Safety and Maintenance of Effect of Asenapine vs. Olanzapine in the Treatment of Subjects With Acute Mania Clinical Trial Protocol A7501006 (Secondary Title: ARES) Completed NCT00143182 Phase 3 Asenapine;Olanzapine
25 The Impact of Sérélys PMS, a Herbal Remedy Based on Pollen Extraction and Saffron, on Symptoms of PMS: A Randomized, Double-blinded, Placebo Controlled Study Completed NCT03298607 Phase 3
26 A Phase III Randomized Double-blind, 12 Week, Placebo Controlled Trial of Transdermal Selegiline in Borderline Personality Disorder (BPD) to Evaluate Efficacy and Safety Completed NCT01912391 Phase 3 Selegiline;Placebo (for Selegiline)
27 Use of Acupuncture In Autistic Spectrum Disorder Completed NCT00346736 Phase 3
28 A Single-Blind Prospective Study of Quetiapine for the Treatment of Mood Disorders in Adolescents Completed NCT00221468 Phase 3 quetiapine
29 Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram Completed NCT00562861 Phase 2, Phase 3 citalopram + mood stabilizer;placebo + mood stabilizer
30 Fluoxetine for the Treatment of Major Depression in Youth With Bipolar Disorder _ Terminated NCT00005015 Phase 3 Fluoxetine
31 Treatment of Schizoaffective Disorder Using Mifepristone Terminated NCT00725270 Phase 2, Phase 3 Mifepristone;Placebo Oral Tablet
32 Optimal Hormone Replacement for Women With Premature Ovarian Insufficiency Withdrawn NCT02922348 Phase 3 Hormone Replacement Therapy;Combined Oral Contraceptives
33 Antibiotic Treatment and Intravenous Immunoglobulin Double-blind, Randomized, Placebo-controlled Trial for PANDAS Unknown status NCT01769027 Phase 2 Sertraline+Antibiotic (penicillin/azithromycin);Sertraline+placebo
34 A Pilot Study: Logan Basic Technique and Auxiliary Abdominal Contacts for Reducing Symptomatology of Primary Dysmenorrhea Unknown status NCT00740818 Phase 2
35 Double-Blind, Placebo-Controlled Study of Depakote (Divalproex Sodium) in Children With Temper Outbursts and Severe Mood Swings Completed NCT00217932 Phase 2 Divalproex Sodium (Depakote)
36 A Phase 2B Study to Determine the Dose Response Pharmacokinetics of TSX-002 (Testosterone) in Hypogonadal Males Completed NCT02222558 Phase 2 TSX-002
37 A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study of NNZ-2566 in Fragile X Syndrome Completed NCT01894958 Phase 2 NNZ-2566;Placebo
38 A Phase 2, Randomized, Double-blind, Dose Response Study of Oral Testosterone in Subjects With Hypogonadism Completed NCT01717768 Phase 2 TSX-002
39 A Double-Blind, Double-Dummy, Placebo-Controlled, Dose Ranging Study of 7.5, 15, and 30 mg of Sublingual Lobeline in Adult ADHD Patients Completed NCT00664703 Phase 2 Lobeline sulfate;Methylphenidate HCl;Placebo
40 A Double-blind Randomized Placebo-controlled Study of Aspirin and N-acetyl Cysteine as Adjunctive Treatments for Bipolar Disorder Patients (SMRI 11T-009) Completed NCT01797575 Phase 2 Aspirin;Sugar Pill
41 Efficacy of Menopause Relief EP-40 - Fixed Combination of Cimicifuga EP-40 and Rhodiola EPR-7 Extracts in Women With Menopausal Symptoms: A Randomized, Double Blind, Placebo Controlled Study Recruiting NCT03461380 Phase 2
42 Effect of Oral Magnesium Supplementation on Anesthesia and Postoperative Analgesia After Surgical Removal of the Lower Third Molars. Active, not recruiting NCT03398382 Phase 1, Phase 2
43 Impact of Nuedexta on Bulbar Physiology and Function in ALS Not yet recruiting NCT03883581 Phase 1, Phase 2 dextromethorphan HBr and quinidine sulfate
44 Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Quetiapine-Referenced, Fixed-Dose Study of Lu AA39959 in the Treatment of Depression in Patients With Bipolar I or II Disorder Terminated NCT00771134 Phase 2 Lu AA39959;Placebo;Quetiapine
45 Randomised, Double-blind, Parallel-group, Placebo-controlled, and Active Referenced Study of Lu AA34893 to Evaluate the Efficacy and Safety of Three Doses Lu AA34893 in the Treatment of Depression in Patients With Bipolar I or II Disorder Terminated NCT00622245 Phase 2 Lu AA34893;Quetiapine fumarate;Placebo
46 A Phase II Study of Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Locally Advanced or Primary Metastatic Breast Cancer Terminated NCT01010854 Phase 2 VPA FEC100
47 A Randomized, Double-Blind Placebo-Controlled Study of 3,5-diiodothyropropionic Acid (DITPA) in Combination With Standard Therapy to Attain NCEP ATP III Goal for LDL Cholesterol in Hypercholesterolemic Patients Terminated NCT00311987 Phase 1, Phase 2 3,5-Diiodothyropropionic acid (DITPA) therapy
48 Therapeutic Schools: Affect Management and HIV Prevention Completed NCT00500487 Phase 1
49 An Affect Management Intervention for Juvenile Offenders Completed NCT00748800 Phase 1
50 A Double-Blind Placebo-Controlled Trial of Dextromethorphan for Treatment of Major Depressive Disorder Completed NCT02860962 Phase 1 Dextromethorphan Hydrobromide

Search NIH Clinical Center for Pseudobulbar Affect

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Quinidine

Genetic Tests for Pseudobulbar Affect

Genetic tests related to Pseudobulbar Affect:

# Genetic test Affiliating Genes
1 Emotional Lability 29

Anatomical Context for Pseudobulbar Affect

MalaCards organs/tissues related to Pseudobulbar Affect:

41
Brain, Breast, Amygdala, Temporal Lobe, Prostate, Heart, Bone Marrow

Publications for Pseudobulbar Affect

Articles related to Pseudobulbar Affect:

(show top 50) (show all 857)
# Title Authors PMID Year
1
The role of overlapping excitatory symptoms in major depression: are they relevant for the diagnosis of mixed state? 38
31132693 2019
2
Psychiatric Adverse Events in Patients Taking Isotretinoin as Reported in a Food and Drug Administration Database From 1997 to 2017. 38
31268488 2019
3
A comparison study assessing neuropsychological outcome of patients with post-operative pediatric cerebellar mutism syndrome and matched controls after proton radiation therapy. 38
31325031 2019
4
Posterior fossa syndrome and increased mean diffusivity in the olivary bodies. 38
31349230 2019
5
Selective Serotonin Reuptake Inhibitor Monotherapy for Anxiety Disorders in Children and Adolescents with Autism Spectrum Disorder: A Chart Review. 38
31295004 2019
6
Case report of severe psychiatric sequelae in a 16-year-old female following resection of a purely dopamine-secreting ganglioneuroma. 38
31394385 2019
7
Patterns of response to antidepressants in major depressive disorder: Drug resistance or worsening of depression are associated with a bipolar diathesis. 38
31227264 2019
8
Personality traits as an organizing framework for personality pathology. 38
31309725 2019
9
The Man Who Saw Things on Carvedilol. 38
31250422 2019
10
Is Emotional Lability Distinct From "Angry/Irritable Mood," "Negative Affect," or Other Subdimensions of Oppositional Defiant Disorder in Children With ADHD? 38
26842831 2019
11
Autosomal Dominant Gene Negative Frontotemporal Dementia-Think of SCA17. 38
30617627 2019
12
Genome-wide analysis of emotional lability in adult attention deficit hyperactivity disorder (ADHD). 38
31085060 2019
13
Establishing a Pediatric Acute-Onset Neuropsychiatric Syndrome Clinic: Baseline Clinical Features of the Pediatric Acute-Onset Neuropsychiatric Syndrome Cohort at Karolinska Institutet. 38
31170007 2019
14
Predictive utility of childhood diagnosis of ICD-10 hyperkinetic disorder: adult outcomes in the MTA and effect of comorbidity. 38
30232561 2019
15
Homozygosity for the A431E mutation in PSEN1 presenting with a relatively aggressive phenotype. 38
30716424 2019
16
Living kidney donor and recipient perspectives on their relationship: longitudinal semi-structured interviews. 38
30948607 2019
17
Mindfulness and negative affectivity in real time: a within-person process model. 38
30909800 2019
18
Pharmaceutical interventions for emotionalism after stroke. 38
30887498 2019
19
Evaluating a scale of excessive mind wandering among males and females with and without attention-deficit/hyperactivity disorder from a population sample. 38
30816143 2019
20
Assessment of Use of Combined Dextromethorphan and Quinidine in Patients With Dementia or Parkinson Disease After US Food and Drug Administration Approval for Pseudobulbar Affect. 38
30615021 2019
21
25 Ventriculoperitoneal Shunt as a Meteorologist: Medtronics Shunt Headaches Vaticinating Climatic Perturbation. 38
30859954 2019
22
Dependency, mood instability, and inconsequence traits for discriminating borderline personality disorder. 38
30843964 2019
23
Differentiating bipolar disorder from borderline personality disorder: Diagnostic accuracy of the difficulty in emotion regulation scale and personality inventory for DSM-5. 38
30699870 2019
24
High Sleep Disturbance and Longer Concussion Duration in Repeat Concussions. 38
30784317 2019
25
Patient experiences of living with chronic leg ulcers and making the decision to seek professional health-care. 38
30724122 2019
26
Negative Affect, Type D Personality, Quality of Life, and Dysfunctional Outcomes of Total Knee Arthroplasty. 38
30719200 2019
27
The Pemoline Model of Self-Injurious Behavior: An Update. 38
31273695 2019
28
Efficacy of amantadine on behavioural problems due to acquired brain injury: A systematic review. 38
31250669 2019
29
Listening to Mozart Improves Current Mood in Adult ADHD - A Randomized Controlled Pilot Study. 38
31156516 2019
30
Inner Dialogical Communication and Pathological Personality Traits. 38
31379684 2019
31
Alice in Wonderland Syndrome as a Presenting Manifestation of Creutzfeldt-Jakob Disease. 38
31143156 2019
32
Dependency, mood instability, and inconsequence traits for discriminating borderline personality disorder. 38
30994782 2019
33
Pseudobulbar Affect in Parkinsonian Disorders: A Review. 38
30732430 2019
34
The effects of emotional lability, mind wandering and sleep quality on ADHD symptom severity in adults with ADHD. 38
30384113 2019
35
The effect of memantine in adult patients with attention deficit hyperactivity disorder. 38
30663824 2019
36
Difficult case of a rare form of familial Alzheimer's disease with PSEN1 P117L mutation. 38
30567237 2018
37
AP-4-Associated Hereditary Spastic Paraplegia 38
30543385 2018
38
An Interesting Case of Carbamazepine-Induced Stevens-Johnson Syndrome. 38
30535610 2018
39
Pseudobulbar affect: Prevalence and association with symptoms in multiple sclerosis. 38
30588376 2018
40
A Major Depressive Disorder in a Patient with Pseudobulbar Affect. 38
30820367 2018
41
Long-term neurological outcomes in out-of-hospital cardiac arrest patients treated with targeted-temperature management. 38
30253227 2018
42
Acute Phase Treatment Outcomes of Electroconvulsive Therapy in Adolescents and Young Adults. 38
30562200 2018
43
Adverse drug events related to mood and emotion in paediatric patients treated for ADHD: A meta-analysis. 38
29883938 2018
44
Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM-II Open Label Study. 38
29477412 2018
45
Measuring child and adolescent emotional lability: How do questionnaire-based ratings relate to experienced and observed emotion in everyday life and experimental settings? 38
29845690 2018
46
Pseudobulbar affect after stroke: a narrative review. 38
30213256 2018
47
Young-Onset Dementia with Lewy Bodies. 38
30687068 2018
48
Pharmacotherapy for the pseudobulbar affect in individuals who have sustained a traumatic brain injury: a systematic review protocol. 38
30204664 2018
49
Maladaptive Personality Traits and 10-Year Course of Psychiatric and Medical Symptoms and Functional Impairment Following Trauma. 38
30010707 2018
50
Pseudobulbar Affect Due to Skull Base Meningioma Resolving After Temporal Lobectomy for Epilepsy. 38
29747704 2018

Variations for Pseudobulbar Affect

ClinVar genetic disease variations for Pseudobulbar Affect:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 46;XY;t(9;11)(q34;p11.2)dn Translocation Pathogenic
2 46;XX;t(2;11)(q11.2;p13)dn Translocation Pathogenic

Expression for Pseudobulbar Affect

Search GEO for disease gene expression data for Pseudobulbar Affect.

Pathways for Pseudobulbar Affect

GO Terms for Pseudobulbar Affect

Sources for Pseudobulbar Affect

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....